10x Genomics (NASDAQ:TXG) Earns Sell (E+) Rating from Weiss Ratings

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

TXG has been the topic of several other research reports. Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. Citigroup reduced their price target on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. UBS Group dropped their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. Finally, Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.86.

10x Genomics Stock Down 3.7 %

Shares of NASDAQ:TXG opened at $14.45 on Friday. The company has a market cap of $1.75 billion, a PE ratio of -9.44 and a beta of 1.85. 10x Genomics has a fifty-two week low of $12.95 and a fifty-two week high of $51.22. The firm has a 50-day simple moving average of $15.14 and a 200 day simple moving average of $17.72.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after acquiring an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics during the 3rd quarter valued at about $35,000. Blue Trust Inc. grew its stake in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares during the last quarter. Sound Income Strategies LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $46,000. Finally, Venturi Wealth Management LLC lifted its stake in 10x Genomics by 1,108.9% during the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after purchasing an additional 2,240 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.